https://ift.tt/qbCSriy from Sanofi - Aventis Groupe https://ift.tt/VYBMd1I via IFTTT " May good health envelop you, spurring a q...
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
https://ift.tt/JzVhxu4 Dupixent ® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age w...
Media Update: Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
https://ift.tt/SXuAEK5 from Sanofi - Aventis Groupe https://ift.tt/xFJciLb via IFTTT " May good health envelop you, spurring a quic...
Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
https://ift.tt/LFGiEX9 Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio from Sanofi - Aventis Groupe http...
Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM
https://ift.tt/N5FdVen from Sanofi - Aventis Groupe https://ift.tt/3RdVSBj via IFTTT " May good health envelop you, spurring a q...
Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
https://ift.tt/4izlXwW from Sanofi - Aventis Groupe https://ift.tt/5Ve82K7 via IFTTT " May good health envelop you, spurring a quic...
Media Update: New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease
https://ift.tt/KICSPgZ from Sanofi - Aventis Groupe https://ift.tt/KNaeq0i via IFTTT " May good health envelop you, spurring a quic...
Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
https://ift.tt/zwy9pdD Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment from Sanofi...
Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
https://ift.tt/oC9faBv from Sanofi - Aventis Groupe https://ift.tt/8ZcuU1Q via IFTTT " May good health envelop you, spurring a quic...
Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs
https://ift.tt/Gb8TPwF from Sanofi - Aventis Groupe https://ift.tt/COeHcgN via IFTTT " May good health envelop you, spurring a q...
Subscribe to:
Posts
(
Atom
)